{"title": "Safety and efficacy of a novel live marker vaccine against Classical swine fever virus", "author": "Dr\u00e4ger; Carolin", "url": null, "hostname": null, "description": "The presented study was dedicated to outstanding issues in regard to the safety and efficacy of the LAV \u201cCP7_E2alf\u201d, during the final licensing process and towards its putative implementation in outbreak scenarios as emergency vaccine. (I) For application of a genetically engineered virus under field conditions, knowledge about its genetic stability is mandatory. Therefore, the genetic stability of \u201cCP7_E2alf\u201d needed to be assessed in vivo and in vitro. Mutation rates were compared to the parental pestivirus strains (BVDV-1 \u201cCP7\u201d and CSFV \u201cAlfort/187\u201d), and BVDV or CSFV field-strains. There was no indication that \u201cCP7_E2alf\u201d could be more prone to mutational events than its parental viruses or representative field-strains. Moreover, no recombination events were observed in in vitro experiments. In conclusion, the data obtained in this study confirm a strong genetic stability of \u201cCP7_E2alf\u201d as an important safety component. (II) Since vaccination of breeding animals is often discussed, this study was conducted to assess the safety of \u201cCP7_E2alf\u201d vaccination of breeding male pigs. The study with \u201cCP7_E2alf\u201d vaccinated boar demonstrated that the new CSFV marker vaccine is suitable for application in reproductive boar. Neither in organs of the uro-genital tract related to sperm production nor in urine or feces, vaccine virus genome was detectable. Dissemination of \u201cCP7_E2alf\u201d through semen, and shedding with urine and feces, is therefore highly unlikely. (III) In order to investigate the influence of pre-existing pestivirus antibodies of the efficacy of \u201cCP7_E2alf\u201d, a vaccination-challenge-trial was conducted with \u201cCP7_E2alf\u201d (Suvaxyn\u00ae CSF Marker) and the \u201cgold-standard\u201d of live-modified CSFV vaccines, the C-strain (RIEMSER\u00ae Schweinepestvakzine). Pre-existing antibodies against BVDV-1 were provoked through intramuscular inoculation of a recent field isolate from Germany. Seven days after the vaccination, all animals were challenged with highly virulent CSFV strain \u201cKoslov\u201d. It was demonstrated that pre-existing anti- BVDV-1 antibodies do not impact the efficacy of both live attenuated vaccines against CSFV. Both C-strain \u201cRiems\u201d and marker vaccine \u201cCP7_E2alf\u201d were able to confer full protection against the highly virulent challenge. However, slight interference was seen with serological DIVA diagnostics accompanying \u201cCP7_E2alf\u201d. Amended sample preparation and combination of test systems was able to resolve most cases of false positive reactions. However, in such a coinfection scenario, optimization and embedding in a well-defined surveillance strategy is clearly needed for marker vaccination scenarios. (IV) To supplement the data about the kinetic of maternally derived antibodies in piglets from sows vaccinated during outbreaks, a single \u201cemergency-type\u201d vaccination of two pregnant sows was done. Focus was laid on the kinetics of maternally derived antibodies (MDA) in the screening assays of their offspring with screening assays that would be used in case of CSFV outbreaks, i.e. CSFV E2 and Erns antibody ELISA. Upon vaccination with \u201cCP7_E2alf\u201d 21 days before farrowing, MDAs were measurable in all piglets born to vaccinated sows. The E2- ELISA reactivities showed an almost linear decrease over ten weeks after which all piglets were tested negative in the ELISA. Future studies should investigate, if MDA are able to protect offspring of vaccinated sows or whether the piglets should also be vaccinated.", "sitename": null, "date": "2018-05-30", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Bitte verwenden Sie diesen Link, wenn Sie dieses Dokument zitieren oder verlinken wollen:\n[https://nbn-resolving.org/urn:nbn:de:gbv:9-002701-7](https://nbn-resolving.org/urn:nbn:de:gbv:9-002701-7)\nSafety and efficacy of a novel live marker vaccine against Classical swine fever virus\n- The presented study was dedicated to outstanding issues in regard to the safety and efficacy of the LAV \u201cCP7_E2alf\u201d, during the final licensing process and towards its putative implementation in outbreak scenarios as emergency vaccine. (I) For application of a genetically engineered virus under field conditions, knowledge about its genetic stability is mandatory. Therefore, the genetic stability of \u201cCP7_E2alf\u201d needed to be assessed in vivo and in vitro. Mutation rates were compared to the parental pestivirus strains (BVDV-1 \u201cCP7\u201d and CSFV \u201cAlfort/187\u201d), and BVDV or CSFV field-strains. There was no indication that \u201cCP7_E2alf\u201d could be more prone to mutational events than its parental viruses or representative field-strains. Moreover, no recombination events were observed in in vitro experiments. In conclusion, the data obtained in this study confirm a strong genetic stability of \u201cCP7_E2alf\u201d as an important safety component. (II) Since vaccination of breeding animals is often discussed, this study was conducted to assess the safety of \u201cCP7_E2alf\u201d vaccination of breeding male pigs. The study with \u201cCP7_E2alf\u201d vaccinated boar demonstrated that the new CSFV marker vaccine is suitable for application in reproductive boar. Neither in organs of the uro-genital tract related to sperm production nor in urine or feces, vaccine virus genome was detectable. Dissemination of \u201cCP7_E2alf\u201d through semen, and shedding with urine and feces, is therefore highly unlikely. (III) In order to investigate the influence of pre-existing pestivirus antibodies of the efficacy of \u201cCP7_E2alf\u201d, a vaccination-challenge-trial was conducted with \u201cCP7_E2alf\u201d (Suvaxyn\u00ae CSF Marker) and the \u201cgold-standard\u201d of live-modified CSFV vaccines, the C-strain (RIEMSER\u00ae Schweinepestvakzine). Pre-existing antibodies against BVDV-1 were provoked through intramuscular inoculation of a recent field isolate from Germany. Seven days after the vaccination, all animals were challenged with highly virulent CSFV strain \u201cKoslov\u201d. It was demonstrated that pre-existing anti- BVDV-1 antibodies do not impact the efficacy of both live attenuated vaccines against CSFV. Both C-strain \u201cRiems\u201d and marker vaccine \u201cCP7_E2alf\u201d were able to confer full protection against the highly virulent challenge. However, slight interference was seen with serological DIVA diagnostics accompanying \u201cCP7_E2alf\u201d. Amended sample preparation and combination of test systems was able to resolve most cases of false positive reactions. However, in such a coinfection scenario, optimization and embedding in a well-defined surveillance strategy is clearly needed for marker vaccination scenarios. (IV) To supplement the data about the kinetic of maternally derived antibodies in piglets from sows vaccinated during outbreaks, a single \u201cemergency-type\u201d vaccination of two pregnant sows was done. Focus was laid on the kinetics of maternally derived antibodies (MDA) in the screening assays of their offspring with screening assays that would be used in case of CSFV outbreaks, i.e. CSFV E2 and Erns antibody ELISA. Upon vaccination with \u201cCP7_E2alf\u201d 21 days before farrowing, MDAs were measurable in all piglets born to vaccinated sows. The E2- ELISA reactivities showed an almost linear decrease over ten weeks after which all piglets were tested negative in the ELISA. Future studies should investigate, if MDA are able to protect offspring of vaccinated sows or whether the piglets should also be vaccinated.\n- Aspekte zur Sicherheit und Effizienz der attenuierten Markervakzine \u201eCP7_E2alf\u201c wurden im Rahmen der hier vorgestellten Arbeit untersucht. Die Studien wurden im Prozess der Lizenzierung des Markerimpfstoffes und zur Einsch\u00e4tzung seines Einsatzes als Notfallimpfstoff durchgef\u00fchrt. (I) Der Einsatz von gentechnisch ver\u00e4nderten Viren im Feld erfordert Studien zu deren genetischen Stabilit\u00e4t. Zur Evaluierung der genetischen Stabilit\u00e4t von \u201eCP7_E2alf\u201c wurden Ko-Infektionsexperimente sowie in vitro- und in vivo-Passage von \u201eCP7_E2alf\u201c, seinem parentalen Virusstamm BVDV-1 \u201eCP7\u201c, des E2-Donorvirus KSPV \u201eAlfort/187\u201c sowie von zwei aktuellen BVDV- und KSPV-Feldst\u00e4mmen durchgef\u00fchrt. Diese Experimente bewiesen die hohe genetische Stabilit\u00e4t von \u201eCP7_E2alf\u201c. Das chim\u00e4re Impfvirus ist nicht weniger stabil als die getesteten Wildtyp-Pestiviren. In den durchgef\u00fchrten Experimenten gab es keine Hinweise f\u00fcr ein h\u00e4ufiges Auftreten von Mutationen oder f\u00fcr Rekombinationsereignissen. (II) Da die Impfung von Zuchttieren oft diskutiert wird, sollte diese Studie dazu dienen die Sicherheit der Impfung von Zuchtebern mit \u201eCP7_E2alf\u201c zu untersuchen. Die Eignung von \u201eCP7_E2alf\u201c f\u00fcr die Immunisierung von Ebern konnte durch eine Impfstudie mit Zuchtebern gezeigt werden. Die Detektion von Impfvirusgenom war weder in den untersuchten Organen, die mit der Sperma-Produktion in Verbindung stehen, noch im Urin oder Kot m\u00f6glich. Es ist somit h\u00f6chst unwahrscheinlich, dass \u201eCP7_E2alf\u201c durch Sperma weitergegeben wird oder dass es zur Ausscheidung \u00fcber Urin oder Kot kommt. (III) In einem Vakzinations-Belastungsinfektionsversuch wurden Schweine mit einem aktuellen deutschen BVDV-1-Stamm intramuskul\u00e4r vorbelastet, anschlie\u00dfend mit \u201eCP7_E2alf\u201c (Suvaxyn\u00ae CSF Marker) und dem \u201eGoldstandard\u201c der Lebend-attenuierten- KSPV Impfstoffe C-Stamm (RIEMSER\u00ae Schweinepestvakzine) geimpft und letztendlich sieben Tage sp\u00e4ter mit dem hochvirulenten KSPV-Stamm \u201eKoslov\u201c belastungsinfiziert. Dieser Versuch bewies, dass vorbestehende BVDV-1 Antik\u00f6rper keinen Einfluss auf die Impfwirkung von \u201eCP7_E2alf\u201c haben. Die geimpften Schweine blieben klinisch unauff\u00e4llig und in den Proben der Tiere wurde kein infekti\u00f6ses KSP-Virus nachgewiesen. Die Entwicklung von KSPV-spezifischen neutralisierenden Antik\u00f6rpern war vergleichbar zwischen Schweinen mit und ohne vorbestehenden BVDV-1 Antik\u00f6rpern. Es konnten jedoch Einfl\u00fcsse auf die verwendete DIVA-Diagnostik beobachtet werden. Diese f\u00fchrten zu falschpositiven Ergebnissen im KSPV Erns DIVA ELISA (Pigtype\u00a9; Qiagen). Die Anzahl der falschpositiven Ergebnisse konnte jedoch durch eine verbesserte Probenvorbereitung und durch Kombination unterschiedlicher Testsysteme stark minimiert werden. F\u00fcr den Einsatz von Markervakzinen ist deren Optimierung und eine Einbettung in eine klar definierte \u00dcberwachungsstrategie notwendig. (IV) Zur Ermittlung der Kinetik von maternalen Antik\u00f6rpern in Ferkeln von Sauen, die w\u00e4hrend Ausbruchsszenarien geimpft wurden, wurde zwei tragenden Sauen eine Notfall\u00e4hnliche einmalige Impfung mit \u201eCP7_E2alf\u201c appliziert. Der Schwerpunkt der Untersuchungen lag auf der Kinetik der maternalen Antik\u00f6rper in den Ferkeln sowie deren Testung in Diagnostik Systemen, die w\u00e4hrend eines Ausbruchs genutzt werden w\u00fcrden. Eine Impfung der Sauen 21 Tage vor dem Geburtstermin f\u00fchrte zu nachweisbaren maternalen Antik\u00f6rpern in den Ferkeln. Testungen im KSPV-E2-ELISA zeigten, dass die Titer der Antik\u00f6rper fast linear abnahmen. Alle Ferkel wurden zehn Wochen nach der Geburt negativ auf anti-KSPV-E2 Antik\u00f6rper getestet. Folgende Versuche sollten sich nun mit den protektierenden Eigenschaften der maternalen Antik\u00f6rper besch\u00e4ftigen.\n|Author:|[urn:nbn:de:gbv:9-002701-7](https://nbn-resolving.org/urn:nbn:de:gbv:9-002701-7)\nCP7_E2alf; Classical swine fever virus; efficacy; live marker vaccine; safety", "language": null, "image": null, "pagetype": null, "links": ["/home/index/language/language/de/rmodule/frontdoor/rcontroller/index/raction/index/docId/1856", "/auth/login/docId/1856/rmodule/frontdoor/rcontroller/index/raction/index", "/home", "/home", "/solrsearch", "/solrsearch/browse", "/publish", "https://ub.uni-greifswald.de/serviceangebote/fuer-wissenschaftlerinnen/publizieren", "javascript:void(0)", "https://nbn-resolving.org/urn:nbn:de:gbv:9-002701-7", "/solrsearch/index/search/searchtype/authorsearch/author/Carolin+Dr%C3%A4ger", "/files/1856/Diss_Draeger_Carolin.pdf", "/citationExport/index/download/docId/1856/output/bibtex", "/citationExport/index/download/docId/1856/output/ris", "http://twitter.com/share?url=https://epub.ub.uni-greifswald.de/frontdoor/index/index/docId/1856", "https://scholar.google.de/scholar?hl=en&q=\"Safety and efficacy of a novel live marker vaccine against Classical swine fever virus\"&as_sauthors=Carolin+Dr\u00e4ger&as_ylo=2017&as_yhi=2017", "javascript:void(0)", "/solrsearch/index/search/searchtype/authorsearch/author/Carolin+Dr%C3%A4ger", "https://nbn-resolving.org/urn:nbn:de:gbv:9-002701-7", "/solrsearch/index/search/searchtype/collection/id/16264", "/solrsearch/index/search/searchtype/collection/id/69", "/home/index/contact", "/home/index/imprint", "/home/index/datenschutz", "/crawlers/sitelinks"]}